Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Ca...
AUSTIN, Texas, May 30, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today an upcoming presentation of findings on key biomarker analysis of colorectal cancer patients treated with Hutruo (MABp1) in its European Phase III study. The abstract, entitled, "Pre-treatment Endogenous Interleukin-1 Receptor Antagonist (IL-1Ra) Levels in Metastatic Colorectal Cancer (mCRC) Patients are Associated with Clinical Outcomes After Anti-Interleukin-1a Therapy (MABp1)", will be presented by renowned oncologist, Dr. Razelle Kurzrock, Chief of Hematology & Oncology, UC San Diego School of Medicine. The data will be presented via poster presentation on Friday, June 30th from 10:30-11am and 4:40-5:10pm at the 19th ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain.
These findings indicate a significant association between pre-treatment circulating levels of IL-1Ra and responsiveness to MABp1 therapy. Lower pre-existing IL-1 antagonist activity was relatively responsive to pharmacological intervention with anti-IL-1alpha antibody therapy. This analysis provides new evidence that regulators of innate immunity may exert selection pressure on tumors and play an active role in the natural history of colorectal cancer. The impact of the body's control of innate inflammation is thus found to affect the use of immune modulating therapy.
"Our analysis show a significant association between pre-treatment circulating levels of IL-1Ra and responsiveness to MABp1 therapy," stated Dr. Kurzrock. She further stated, "These results provide new insight on the active role for interleukin-1 regulation in disease progression in colorectal cancer and could help us create more personalized approaches to treatment of the disease."
About Razelle Kurzrock, M.D.
Dr. Kurzrock is a medical oncologist and a renowned expert in precision medicine. She is a thought leader in the use of anti-cytokine therapies for the treatment of cancer and one of the first to recognize the importance of the interleukin-1 pathway in cancer. While at the University of Texas MD Anderson Cancer Center, Dr. Kurzrock built one of the most successful Phase 1 clinical trials programs in the nation, and was the senior author in the pioneering study for the Company's colorectal cancer study. Dr. Kurzrock currently serves as Senior Deputy Center Director for Clinical Science, Director at the Center for Personalized Cancer Therapy, Director of the Clinical Trials Office, and a Team Leader for Experimental Therapeutics at the Moores Cancer Center at UC San Diego. Dr. Kurzrock is also Chief of the Hematology & Oncology Division in the UC San Diego School of Medicine. Dr. Kurzrock serves on XBiotech's Scientific Advisory Board.
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Concurrent Stockholders Approve Proposal to Sell Content Delivery & Storage Business to Vecima Networks13.12.2017 22:47 | Pressemelding
ATLANTA , December 13, 2017 - The stockholders of Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation, and delivery of visual media assets, have approved all proposals presented at a special meeting of its stockholders held on December 13, 2017. The proposals related to the sale of Concurrent's content delivery and storage business to Vecima Networks Inc. (TSX:VCM). Derek Elder, President and CEO of Concurrent, commented, "The Board of Directors and our management team appreciate the overwhelming support of our proposals from Concurrent's stockholders. We expect to close the announced transaction with Vecima Networks by the end of the calendar year. The investment committee established by the Board of Directors will continue to evaluate options to maximize the value of the Company's remaining assets after the close of the sale to Vecima." The specific voting results for each of the proposals considered at the special stockholder's
TrueCommerce Announces Integration with AccountMate Business Management Solution13.12.2017 22:14 | Pressemelding
Industry-leading cloud-based EDI solution provides immediate compliance with trading partners and seamless integration with AccountMate PITTSBURGH, Dec. 13, 2017 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, has announced today the availability of integration with AccountMate, one of the market's most flexible ERP systems that is leveraged by over 125,000 users across 200 industries. AccountMate customers now have access to TrueCommerce's global commerce network that provides seamless connectivity and integration with the top 500 North American and European retailers, as well as thousands of other retail outlets, distributors and logistics organizations. "AccountMate is a well-established ERP system provider considered to be one of the world's most flexible accounting and business management software packages," said TrueCommerce president Ross Elliott. "TrueCommerce made a strategic decision t
STEM Designation Granted for SMU Cox Master of Science in Finance13.12.2017 21:46 | Pressemelding
MSF Students Will be Eligible to Apply for STEM OPT Extension Dallas, Texas (SMU), USA, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Beginning in the fall semester of 2018, the SMU Cox Master of Science in Finance degree (MSF) will be STEM-designated. The Board of Trustees of Southern Methodist University in Dallas, Texas, at its December meeting, approved changes to the MS in Finance program curriculum and the request to change the classification of instructional programs (CIP) code. Based on these changes, the SMU Cox MSF program now falls under fields of study considered to be science, technology, engineering and math (STEM). The government of the United States considers expertise in these fields an important driver of innovation and job creation. According to the U.S. Department of Homeland Security, the country is currently facing a shortage of qualified candidates for STEM jobs. As a result, international students completing STEM-designated programs in the U.S. are encouraged to stay
Hitachi Vantara Continues To Bolster Its Global Leadership Team With New Executive Appointments13.12.2017 15:00 | Pressemelding
SANTA CLARA, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced new appointments to its global leadership team: Mark Ablett has been named senior vice president of global go-to-market (GTM) strategy and Daniel Chong has been named senior vice president of Asia Pacific (APAC). Both will report to the company's chief revenue officer, Hans-Peter Klaey. Ablett previously served as Hitachi Vantara's senior vice president (SVP) of APAC, where he helped Hitachi Vantara's APAC theatre to achieve record growth. In his new role, Ablett will be responsible for developing the company's global GTM strategy, partnering with Hitachi Vantara's customers to help them successfully navigate and execute complex digital transformation journeys. Prior to joining Hitachi, Ablett held executive positions with Juniper Networks and SpectraLink, among others. Chong will assume Ablett's former post as SVP of APAC
DTLR Selects ShopperTrak Traffic Insights to Optimize Store Performance13.12.2017 12:11 | Pressemelding
Lifestyle retailer uses ShopperTrak to better understand key metrics and customer insights CHICAGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyco Retail Solutions today announced that DTLR Inc., a US lifestyle retailer, has selected its ShopperTrak in-store traffic analytics solution, to provide shopper behavior insights across all 107 stores in 12 states and Washington D.C. Following a successful pilot, DTLR deployed the ShopperTrak perimeter analytics solution and related advisory services to position the importance of shopper traffic, conversion, and other key metrics across the organization. ShopperTrak advisory services utilized include store segmentation, peer grouping, goal setting and field-level training to help better understand shopper traffic and how to best leverage the new data insights. "We sought a vendor who could offer perspective on our operational activities and provide tangible ways to optimize in-store performance," said Frank Long, vice president of
Percona Collaborates with AWS on Database Delivery Service13.12.2017 09:02 | Pressemelding
Percona Managed Services to Ensure Customers Running Open Source Databases on AWS Take Optimal Advantage of AWS Resources RALEIGH, N.C., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced collaboration with Amazon Web Services (AWS) to serve as an AWS Standard Tier Consulting Partner and Amazon Aurora Service Delivery Partner in the AWS Partner Network (APN). Percona provides managed services to support the use of Amazon Elastic Compute Cloud (Amazon EC2), Amazon Relational Database Service (Amazon RDS), and Amazon Aurora on the flexible, scalable, pay-as-you-go AWS. Percona also announced Percona Monitoring and Management 1.5 with improved support for MySQL on Amazon RDS and Amazon Aurora MySQL. Migrating workloads to AWS can be a vital part of improving customer experience, gaining deeper business insights and increasing efficiency. Whether
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom